Tandem Labs offers the following service categories for metabolite screening and identification:
Applicable to the early stage screening of compounds where the objective is to improve the PK/PD characteristics of compounds within a series that are built upon a common scaffold, e.g., identification and design mediation of compound-metabolic 'hot spots'.
Applicable to the later stages of discovery where the objective may be the optimization of a lead candidate compound(s) PK/PD, e.g., determination of specific sites of hydroxylation and oxidation, among others, and their relative rates.
Applicable to compound development (non-clinical or clinical) or candidate nomination where the objective is to comprehensively identify the full range of drug compound metabolites to assist in the design of their respective development programs, e.g., the identification of species-specific metabolites and metabolites for safety testing (MIST), among others.
| Technology | Process | ||||
|---|---|---|---|---|---|
| Service Category | Data Collection | Mass Accuracy | Outcomes | ||
| LC/MS/MS | Metabolite Screening and Surveying | MRM Scan | Unit Mass |
• Common metabolic alterations • May not identify modification sites1 • Cannot identify modification types (e.g., -NH2 vs. -O) |
|
| Precursor Ion Scan | |||||
| Precursor Ion Scan | |||||
| Neutral Loss Scan | |||||
| LC-QTOF | Metabolite Surveying, ID, and Pathways | LC/MS | Accurate Mass |
• Common metabolic alterations • May not identify modifications sites1 • Identify modifications types (e.g., -NH2 vs. -O) |
|
| LC/MS/MS | |||||
| MALDI-TOF | Metabolite ID and Pathways | MS | Accurate Mass |
• Common metabolic alterations • May not identify modifications sites1 • Identify modifications types3 (e.g., -NH2 vs. -O) |
|
| MS/MS | |||||
|
NOTES 1 - Site of modifications contingent upon LC separation. 2 - High accurate mass MS/MS may enable determination of site modifications 3 - High energy accurate mass MS/MS enables determination of site modification. |
|||||
